Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 6:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 216 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Exposure Therapy + Placebo Clear all
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Noise-Induced Hearing Loss-Acute Exposure Treatment (UA)

NCT04774250
View directory record Official record
Conditions
Hearing Loss, Noise-Induced
Interventions
Zonisamide 100Mg Cap, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Sep 30, 2026, 6:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Electrophysiological Effects of Potential QT Prolonging Drugs

NCT05716854
View directory record Official record
Conditions
Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics
Interventions
Clarithromycin, Pimozide, Placebo (Part 1), Moxifloxacin, Cobicistat, Moxifloxacin and Cobicistat, Placebo (Part 2)
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Sep 30, 2026, 6:43 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Positive Affect Treatment for Adolescents With Early Life Adversity

NCT06273137
View directory record Official record
Conditions
Depression
Interventions
Positive affect treatment, Supportive psychotherapy (SUP)
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
12 Years to 16 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 30, 2026, 6:43 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Substance Use

NCT00430573
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
D-cycloserine, Placebo
Drug
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Sep 30, 2026, 6:43 AM EDT
Enrolling by invitation Phase 2 Interventional

Bright Light Therapy for Depressed Geriatric Inpatients

NCT07002554
View directory record Official record
Conditions
Unipolar Depression
Interventions
Bright light therapy, dim red light
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 30, 2026, 6:43 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pre-Exposure Prophylaxis in YMSM

NCT01033942
View directory record Official record
Conditions
HIV
Interventions
coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP, Placebo, Many Men, Many Voices (3MV)
Drug · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 22 Years · Male only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 30, 2026, 6:43 AM EDT
Recruiting No phase listed Observational

Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users

NCT06659029
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Anifrolumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
Female only
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 30, 2026, 6:43 AM EDT
Completed Not applicable Interventional Results available

Medicinal Nicotine for Preventing Cue Induced Craving

NCT02347605
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Nicotine lozenge 4 mg, Placebo lozenge
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Sep 30, 2026, 6:43 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Neural Circuits in Women With Abuse and Posttraumatic Stress Disorder

NCT01681849
View directory record Official record
Conditions
PTSD
Interventions
Placebo, Paroxetine, Positron Emission Tomography (PET) Imaging
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Sep 30, 2026, 6:43 AM EDT
Completed Phase 2 Interventional Results available

Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder

NCT00790868
View directory record Official record
Conditions
Panic Disorder
Interventions
d-cycloserine, placebo
Drug
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
4
States / cities
Hartford, Connecticut • Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Sep 30, 2026, 6:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Food Exposure Therapy in Anorexia Nervosa

NCT00755820
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Exposure Therapy + D-Cycloserine, Exposure Therapy + Placebo, Supportive Psychotherapy
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2012 · Synced Sep 30, 2026, 6:43 AM EDT
Withdrawn Phase 2 Interventional

Celecoxib in Preventing Skin Cancer

NCT00025051
View directory record Official record
Conditions
Non-melanomatous Skin Cancer
Interventions
celecoxib, anti-cytokine therapy, antiangiogenesis therapy, biological therapy, cancer prevention intervention, chemoprevention of cancer, growth factor antagonist therapy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
20 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2013 · Synced Sep 30, 2026, 6:43 AM EDT
Completed Not applicable Interventional

Augmenting Exposure Therapy With an N-Methyl-D-Aspartate (NMDA) Agonist for Panic Disorder

NCT00131339
View directory record Official record
Conditions
Panic Disorder
Interventions
Cognitive behavioral therapy, D-cycloserine
Behavioral · Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Hartford, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2009 · Synced Sep 30, 2026, 6:43 AM EDT
Completed Phase 2 Interventional

Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma

NCT00734292
View directory record Official record
Conditions
Mild to Moderate Asthma
Interventions
fluticasone propionate, formoterol fumarate, fluticasone propionate, formoterol fumarate
Drug · Other
Lead sponsor
SkyePharma AG
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
8
States / cities
Anaheim, California • Mission Viejo, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Sep 30, 2026, 6:43 AM EDT
Completed Not applicable Interventional

Distal Peripheral Neuropathy in Type 2 Diabetes

NCT05104047
View directory record Official record
Conditions
Peripheral Neuropathy, Pain, Neuropathic, Diabetes
Interventions
Moxibustion - Traditional (Active), Moxibustion - Smokeless - (Active), Placebo Moxibustion
Other
Lead sponsor
New York University
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 30, 2026, 6:43 AM EDT
Completed Not applicable Interventional

Conditioned Open-label Placebo (COLP) for Peri-operative Pain Management in Patients With Head and Neck Cancer

NCT04973748
View directory record Official record
Conditions
Postoperative Pain, Opioid Use
Interventions
Conditioned open-label placebo (COLP), Surveys about pain, opioid use and depression symptoms
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Sep 30, 2026, 6:43 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Noise-Induced Hearing Loss-Acute Exposure Treatment

NCT04768569
View directory record Official record
Conditions
Hearing Loss, Noise-Induced
Interventions
Zonisamide 100Mg Cap, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Sep 30, 2026, 6:43 AM EDT
Active, not recruiting Phase 3 Interventional

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

NCT06456346
View directory record Official record
Conditions
Essential Thrombocythemia
Interventions
Bomedemstat, Hydroxyurea, Bomedemstat placebo, Hydroxyurea placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
22
States / cities
Glendale, Arizona • Glendale, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 30, 2026, 6:43 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Light Therapy for Depression in Adolescent Outpatients

NCT05823090
View directory record Official record
Conditions
Depression, Adolescent - Emotional Problem
Interventions
light box (Carex DayLight Classic Model)
Device
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
12 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Sep 30, 2026, 6:43 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Effects of Low-Level Laser Stimulation With and Without Fear Extinction Training

NCT02926352
View directory record Official record
Conditions
Phobias, Claustrophobia, Social Phobia
Interventions
Extinction Training, Low-Level Laser Therapy, Sham Low-Level Laser Therapy
Behavioral · Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Sep 30, 2026, 6:43 AM EDT
Completed Phase 2 Interventional Results available

Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations

NCT02130193
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 70 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Sep 30, 2026, 6:43 AM EDT
Completed Phase 4 Interventional Results available

Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)

NCT02560389
View directory record Official record
Conditions
Stress Disorder, Post Traumatic
Interventions
Placebo, Levodopa
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
25 Years to 50 Years · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Sep 30, 2026, 6:43 AM EDT
Recruiting Phase 2 Interventional

A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT07491458
View directory record Official record
Conditions
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
HU6, Placebo
Drug · Other
Lead sponsor
Rivus Pharmaceuticals, Inc.
Industry
Eligibility
30 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
31
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 30, 2026, 6:43 AM EDT
Completed Phase 3 Interventional Results available

A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)

NCT04093024
View directory record Official record
Conditions
Lung Diseases, Interstitial
Interventions
Nintedanib, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
6 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 30, 2026, 6:43 AM EDT